NewAmsterdam Pharma Co N.V. (NAMS) shareholders
Close on Nov 17, 2026Market cap $2.32BP/E –Yield –
Ownership
Who owns NewAmsterdam Pharma's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Capital World Investors | 12,188,377 | 10.40% | 13G (passive) amendment | May 29, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (10.00%) | 11,941,763 | 10.00% | 13G (passive) amendment | Sep 30, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 11,063,125 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 10,875,454 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Fhmlsp, L.L.C. Joint filing with Frazier Life Sciences Public Fund, L.P. (8.70%), Fhmlsp, L.P. (8.70%) and 5 more | 10,424,224 | 8.70% | 13D (active) amendment | Sep 18, 2026 |
| ForGrowth NAP B.V. | 9,316,914 | 8.30% | 13D (active) amendment | Sep 26, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (7.60%) | 8,765,811 | 7.60% | 13G (passive) amendment | Mar 31, 2026 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.P. (7.70%), Fhmlsp, L.L.C. (7.70%) and 5 more | 8,623,939 | 7.70% | 13D (active) amendment | Nov 1, 2025 |
| Patrick J. Heron Joint filing with Fhmls X, L.P. (6.50%), Fhmls X, L.L.C. (6.50%) and 5 more | 7,327,937 | 6.50% | 13D (active) amendment | Aug 18, 2025 |
| Viking Global Investors LP Joint filing with Viking Global Opportunities Parent GP LLC (6.50%), Halvorsen Ole Andreas (6.50%) and 2 more | 6,978,534 | 6.50% | 13G (passive) amendment | Dec 31, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer, Director | 122,802 | Oct 2, 2026 |
| Michael H. Davidson | Chief Executive Officer, Director | 1,078,638 | Sep 15, 2026 |
| Robert William Gunning | Vice President, Controller | 3,200 | Sep 3, 2026 |
| Louise Frederika Kooij | Chief Accounting Officer | 49,353 | Jul 22, 2026 |
| Mayur Ian Somaiya | Chief Financial Officer | 98,166 | Jan 22, 2026 |
| Douglas F. Kling | Chief Operating Officer | 44,000 | Jul 17, 2025 |
| Michael F. Marino III | See Remarks | 55,000 | Jun 3, 2025 |
| Juliette Berangere Audet | See Remarks | 15,104 | May 2, 2025 |
| William A. Jones Jr | Chief Commercial Officer | 43,000 | Jan 7, 2025 |
| John W. Smither | Director | 8,760 | Sep 9, 2026 |
| Louis G. Lange | Director | 10,806 | Mar 12, 2026 |
| der Kamp Hilde Johanna van | Director | 10,360 | Jan 9, 2026 |
| William Lewis | Director | 10,360 | Jan 9, 2026 |
| Mark C. McKenna | Director | 10,360 | Jan 9, 2026 |
| Adele M. Gulfo | Director | 14,260 | Jan 9, 2026 |
| James N. Topper | Director | 6,829,524 | Sep 17, 2025 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion | 10% owner | – | Jan 2, 2025 |
| Growth Management B.V. Forbion | 10% owner | 11,316,472 | Jan 2, 2025 |
| NAP B.V. ForGrowth | 10% owner | 10,656,172 | Jan 2, 2025 |
| IV Management B.V. Forbion | 10% owner | 10,760,928 | Jan 2, 2025 |
| Capital Fund IV Cooperatief U.A. Forbion | 10% owner | 10,686,018 | Jan 2, 2025 |
| Bain Capital Life Sciences III General Partner, LLC | 10% owner | – | Dec 17, 2024 |
| BCLS Fund III Investments, LP | 10% owner | – | Dec 17, 2024 |
| Bain Capital Life Sciences Investors II, LLC | 10% owner | – | Dec 17, 2024 |
| BCIP Life Sciences Associates, LP | 10% owner | – | Dec 17, 2024 |
| BCLS II Investco, LP | 10% owner | – | Dec 17, 2024 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | – | Dec 17, 2024 |
| BCLS II Investco (GP), LLC | 10% owner | – | Dec 17, 2024 |
| Bain Capital Life Sciences Fund II, L.P. | 10% owner | – | Dec 17, 2024 |
| Bain Capital Life Sciences Fund III, L.P. | 10% owner | 10,473,913 | Dec 17, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Sep 30, 2026 | Sale(10b5-1 plan) | −50,246 | $25.03 | $1.26M | 69,302 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Sep 30, 2026 | Option exercise | +50,246 | – | – | 119,548 |
| Michael H. Davidson Chief Executive Officer, Director | Sep 14, 2026 | Buy | +10,000 | $22.65 | $226.50K | 792,923 |
| John W. Smither Director | Sep 4, 2026 | Sale | −1,600 | $25.32 | $40.51K | 8,760 |
| Robert William Gunning Vice President, Controller | Sep 1, 2026 | Award | +3,200 | – | – | 3,200 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Aug 24, 2026 | Option exercise | +125,000 | – | – | 194,302 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Aug 24, 2026 | Sale(10b5-1 plan) | −125,000 | $26.91 | $3.36M | 69,302 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Option exercise | +25,000 | $11.90 | $297.50K | 49,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Option exercise | +80,000 | $11.17 | $893.60K | 129,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Sale(10b5-1 plan) | −70,200 | $29.96 | $2.10M | 59,153 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Sale(10b5-1 plan) | −31,885 | $31.05 | $990.03K | 27,268 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Sale(10b5-1 plan) | −2,915 | $31.71 | $92.43K | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −39,700 | $30.20 | $1.20M | 24,653 |
| Louise Frederika Kooij Chief Accounting Officer | Jun 22, 2026 | Option exercise | +25,000 | $10.90 | $272.50K | 49,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jun 22, 2026 | Option exercise | +15,000 | $11.90 | $178.50K | 64,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −300 | $30.73 | $9.22K | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | May 26, 2026 | Option exercise | +60,000 | $10.00 | $600.00K | 84,353 |
| Louise Frederika Kooij Chief Accounting Officer | May 26, 2026 | Sale(10b5-1 plan) | −65,000 | $35.69 | $2.32M | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | May 26, 2026 | Option exercise | +5,000 | $10.90 | $54.50K | 89,353 |
| Louis G. Lange Director | Mar 11, 2026 | Sale | −44,173 | $30.41 | $1.34M | 10,806 |
| Louis G. Lange Director | Mar 11, 2026 | Sale | −446 | $31.23 | $13.93K | 10,360 |
| Louis G. Lange Director | Mar 9, 2026 | Option exercise | +44,619 | $11.50 | $513.12K | 54,979 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 9, 2026 | Option exercise | +101,409 | – | – | 170,711 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −101,409 | $30.29 | $3.07M | 69,302 |
| Louis G. Lange Director | Mar 6, 2026 | Sale | −28,186 | $29.41 | $828.95K | 0 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 6, 2026 | Sale(10b5-1 plan) | −94,124 | $30.32 | $2.85M | 69,302 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 6, 2026 | Option exercise | +94,124 | – | – | 163,426 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 5, 2026 | Sale(10b5-1 plan) | −104,467 | $30.30 | $3.17M | 69,302 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 5, 2026 | Option exercise | +104,467 | – | – | 173,769 |
| Michael H. Davidson Chief Executive Officer, Director | Mar 2, 2026 | Option exercise | +443,707 | – | – | 617,851 |
| Michael H. Davidson Chief Executive Officer, Director | Mar 2, 2026 | Sale | −443,707 | $33.25 | $14.75M | 174,144 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 26, 2026 | Sale(10b5-1 plan) | −17,924 | $34.44 | $617.30K | 174,144 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 26, 2026 | Sale(10b5-1 plan) | −165,408 | $33.63 | $5.56M | 477,783 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 26, 2026 | Option exercise | +183,332 | – | – | 643,191 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 25, 2026 | Sale(10b5-1 plan) | −1,300 | $36.68 | $47.68K | 459,859 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 25, 2026 | Sale(10b5-1 plan) | −10,436 | $35.96 | $375.28K | 461,159 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 25, 2026 | Sale(10b5-1 plan) | −46,517 | $35.11 | $1.63M | 471,595 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 25, 2026 | Option exercise | +58,253 | – | – | 518,112 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −3,161 | $36.46 | $115.25K | 459,859 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −61,547 | $36.13 | $2.22M | 463,020 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 24, 2026 | Option exercise | +64,708 | – | – | 524,567 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Feb 20, 2026 | Sale | −14,692 | $35.00 | $514.22K | 84,289 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Feb 20, 2026 | Sale | −30,789 | $35.46 | $1.09M | 53,500 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 28, 2026 | Sale(10b5-1 plan) | −32,612 | $31.80 | $1.04M | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 28, 2026 | Option exercise | +32,612 | $10.90 | $355.47K | 56,965 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 27, 2026 | Option exercise | +39,816 | $10.90 | $433.99K | 64,169 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 27, 2026 | Sale(10b5-1 plan) | −39,816 | $32.62 | $1.30M | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 26, 2026 | Sale(10b5-1 plan) | −309 | $33.45 | $10.34K | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 26, 2026 | Sale(10b5-1 plan) | −34,091 | $32.77 | $1.12M | 24,662 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 26, 2026 | Option exercise | +34,400 | $10.90 | $374.96K | 58,753 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 23, 2026 | Sale(10b5-1 plan) | −12,767 | $34.37 | $438.80K | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 23, 2026 | Sale(10b5-1 plan) | −25,405 | $33.44 | $849.54K | 37,120 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 23, 2026 | Option exercise | +38,172 | $10.90 | $416.07K | 62,525 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 21, 2026 | Option exercise | +39,784 | $9.26 | $368.40K | 98,166 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −15,422 | $33.25 | $512.78K | 82,744 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −24,362 | $33.80 | $823.44K | 58,382 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −900 | $30.64 | $27.58K | 117,698 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −39,712 | $31.78 | $1.26M | 77,986 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −19,604 | $32.38 | $634.78K | 58,382 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 20, 2026 | Option exercise | +60,216 | $9.26 | $557.60K | 118,598 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NewAmsterdam Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 115,916 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Johannes Jacob Pieter Kastelein Affiliate | Aug 25, 2026 | 250,000 | $6.97M | Aug 25, 2026 | Option Exercise |
| Johannes Jacob Pieter Kastelein Affiliate | Aug 24, 2026 | 125,000 | $3.48M | Aug 24, 2026 | Option Exercise |
| Louise Frederika Kooij Officer | May 26, 2026 | 210,000 | $7.44M | May 26, 2026 | Stock Option Exercise |
| Louis G. Lange Affiliate | Mar 11, 2026 | 44,619 | $1.40M | Mar 11, 2026 | Warrant Exercise |
| Louis G. Lange Affiliate | Mar 6, 2026 | 28,186 | $878.84K | Mar 6, 2026 | RSU Award |
| Johannes Jacob Pieter Kastelein Affiliate | Mar 5, 2026 | 300,000 | $9.35M | Mar 2, 2026 | Option Exercise |
| Michael H. Davidson Affiliate | Mar 2, 2026 | 443,707 | $15.73M | Mar 2, 2026 | Option Exercise |
| Michael H. Davidson Affiliate | Feb 24, 2026 | 750,000 | $27.13M | Feb 24, 2026 | Option Exercise |
| Johannes Jacob Pieter Kastelein Officer, Director | Feb 20, 2026 | 45,481 | $1.58M | Feb 20, 2026 | Vesting of RSU Grant |
| Mayur Ian Somaiya Affiliate | Jan 20, 2026 | 200,000 | $6.33M | Jan 20, 2026 | Stock Option Exercise |
| Michael H. Davidson affiliate | Jan 7, 2026 | 11,582 | $410.89K | Jan 7, 2026 | Vesting of RSU Grant |
| Douglas F. Kling Affiliate | Jan 6, 2026 | 300,000 | $10.04M | Jan 6, 2026 | Stock Option Exercise |
| Mayur Ian Somaiya affiliate | Jan 5, 2026 | 5,118 | $170.17K | Jan 5, 2026 | Vesting of RSU Grant |
| Johannes Kastelein Affiliate | Jan 5, 2026 | 6,000 | $199.50K | Jan 5, 2026 | Vesting of RSU Grant |
| Louise Frederika Kooij affiliate | Jan 5, 2026 | 2,647 | $88.01K | Jan 5, 2026 | Vesting of RSU Grant |
See a number that looks wrong?